The IAS–USA 30th Annual Update on HIV Management in Atlanta, Georgia

The IAS–USA 30th Annual Update on HIV Management in Atlanta, Georgia

Registration Details

  • In-Person Registration: $95.00 (USD)
  • In-Person Registration ends: Sunday, April 3, 2022
  • In-Person Fellows: $25.00 (USD)
  • In-Person Fellows ends: Sunday, April 3, 2022
  • Virtual Registration: $35.00 (USD)
  • Virtual Registration ends: Friday, April 8, 2022
  • Virtual Fellows: $25.00 (USD)
  • Virtual Fellows ends: Friday, April 8, 2022

Faculty

Grant Ellsworth, MD, MS
Weill Cornell Medicine
Rajesh T. Gandhi, MD
Harvard Medical School
Jeffrey L. Lennox, MD
Emory University School of Medicine
Michael S. Saag, MD
University of Alabama at Birmingham
Dawn K. Smith, MD, MS, MPH
Centers for Disease Control and Prevention
Melanie Thompson, MD
Melanie A. Thompson, MD
Thacker & Thompson, MD

Panelists

Meredith E. Clement, MD
Louisiana State University Health Sciences Center
Khalil G. Ghanem, MD, PhD
Khalil G. Ghanem, MD, PhD
Johns Hopkins University School of Medicine
Kimberly A. Workowski, MD
Emory University

Special Panelists

James Curran, MD, MPH
Emory University School of Medicine
Jonathan Kaplan, MD
Centers for Disease Control and Prevention
Harold Jaffe, MD
Centers for Disease Control and Prevention
David Rimland, MD
Emory University School of Medicine
Melanie Thompson, MD
Melanie A. Thompson, MD
Thacker & Thompson, MD

April 8, 2022

9:30 AM - 5:00 PM ET

Address

Cobb Galleria Centre - Ballroom
2 Galleria Parkway
Atlanta
Georgia
30339
United States

For in-person attendees, there is a special panel session at the close of the course:

Special Panel Session: 40 Years Later: Looking Back at the Beginning of the HIV/AIDS Epidemic in Atlanta, Georgia. From the Perspectives of People Who Were There From the Beginning

Moderators: Jeffrey Lennox, MD, and Michael Saag, MD
Panelists: James Curran, MD, MPH, Jonathan Kaplan, MD, Harold Jaffe, MD, David Rimland, MD, and Melanie Thompson, MD

For those attending in person, proof of vaccination and wearing a mask at all times during the course will be required, as well as any other measure(s) the IAS–USA sets forth to help us ensure our attendees are safe.

Agenda

Last Modified: May 11, 2022 @ 10:05 AM

Program Description

This live course will consist of an in-person component as long as it is safe and practical to do so. There will also be a simultaneous virtual component for those unable to travel.

This live course will focus on recent advances in HIV medicine including updates from CROI 2022, new antiretroviral formulations and strategies, key assessments for older people with HIV, new advances for screening and treating for anal dysplaxia, and implementing new guidelines for  preexposure prophylaxis. This course will feature 2 case-based panel discussions on antiretroviral therapy and controversies and management of sexually transmitted infections.

For in-person attendees, there is a special panel session at the close of the course, “Looking Back at the Beginning of the HIV/AIDS Epidemic in Atlanta, Georgia.”

For those attending in person, proof of vaccination and wearing a mask at all times during the course will be required, as well as any other measure(s) the IAS–USA sets forth to help us ensure our attendees are safe.

Assessment of Needs

Rapid advances in HIV disease management and COVID-19 information require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV, COVID-19, and sexually transmitted infections. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

  • Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Describe the most current data from recent scientific conferences, including research on new and investigational antiretroviral drugs and approaches and COVID-19
  • Describe the current epidemiology, clinical presentations, and management of the most common sexually transmitted infections (STIs) in adults with HIV infection
  • Describe how and when to conduct frailty and cognition assessments for older patients with HIV
  • Describe how to screen for anal cancer and what the real-world implications are in your practice

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV or COVID-19 research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 5.25 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 5.25 contact hours (0.525 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN  # 0761-9999-22-293-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

BRONZE SUPPORTER

Theratechnologies, Inc.

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.